OSCIFLEX LLC
Developing technologies for venous disease based on molecular insights
PHILADELPHIA, United States · Founded 2019 · $3.1M raised
- Headquarters
- PHILADELPHIA, Pennsylvania
- Employees
- 1–10
- Founded
- 2019
- Business Model
- B2B
- Website
- osciflex.com
- Total Funding
- $3.1M
- Last Round
- $375K SeedJan 2022
- Rounds
- 3
About
OsciFlex develops medical technologies for the prevention of venous thromboembolism (VTE) in hospitalized patients. Founded by researchers from the University of Pennsylvania, the company's OsciFlex System uses pneumatic actuation to drive rapid foot flexion and compression, stimulating calf muscle contraction to prevent dangerous blood clots. VTE is the leading cause of preventable hospital deaths in the US, affecting 300,000–600,000 patients annually.
Summary
OSCIFLEX LLC is a Biotech company based in PHILADELPHIA, United States, founded in 2019. It has raised $3.1M in total across 3 rounds, most recently a $375K Seed round in Jan 2022. Investors include NIH.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — 25 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2022
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.